Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Deadly Switzerland ski resort fire was likely started by sparklers attached to champagne bottles, officials say - 2Reports: Germany plans expansion of foreign intelligence powers
- 32024 Style: The It-Things You Want in Your Closet
- 4The most effective method to Pick the Right Volvo XC40 Trim for Your Way of life
- 5Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings
- California officials warn against foraging wild mushrooms after deadly poisoning outbreak
- Lily Allen 2026 'West End Girl' Tour: How to get tickets, prices, presale info and more
- Step by step instructions to Pick the Right Dental specialist for Your Dental Inserts Technique
- Vote In favor of Your Favored IT Administration
- Israel's fractured opposition hands Netanyahu a full term
- EPA watchdog finds nation’s most contaminated sites are vulnerable to flooding, wildfires
- From Loner to Force to be reckoned with: Individual Accounts of Change
- 2 of Earth's rarest lightning phenomena captured simultaneously in once-in-a-lifetime photo
- Understanding the Rudiments of Tree Administrations
